196 related articles for article (PubMed ID: 25269459)
1. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.
Siricilla S; Mitachi K; Wan B; Franzblau SG; Kurosu M
J Antibiot (Tokyo); 2015 Apr; 68(4):271-8. PubMed ID: 25269459
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Sansanmycin Analogues as Potent
Tran W; Kusay AS; Hawkins PME; Cheung CY; Nagalingam G; Pujari V; Ford DJ; Stoye A; Ochoa JL; Audette RE; Hortle E; Oehlers SH; Charman SA; Linington RG; Rubin EJ; Dowson CG; Roper DI; Crick DC; Balle T; Cook GM; Britton WJ; Payne RJ
J Med Chem; 2021 Dec; 64(23):17326-17345. PubMed ID: 34845906
[TBL] [Abstract][Full Text] [Related]
3. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.
Siricilla S; Mitachi K; Skorupinska-Tudek K; Swiezewska E; Kurosu M
Anal Biochem; 2014 Sep; 461():36-45. PubMed ID: 24939461
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.
Hotoda H; Furukawa M; Daigo M; Murayama K; Kaneko M; Muramatsu Y; Ishii MM; Miyakoshi S; Takatsu T; Inukai M; Kakuta M; Abe T; Harasaki T; Fukuoka T; Utsui Y; Ohya S
Bioorg Med Chem Lett; 2003 Sep; 13(17):2829-32. PubMed ID: 14611838
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimycobacterial activities of capuramycin analogues.
Reddy VM; Einck L; Nacy CA
Antimicrob Agents Chemother; 2008 Feb; 52(2):719-21. PubMed ID: 18070956
[TBL] [Abstract][Full Text] [Related]
6. Improved synthesis of capuramycin and its analogues.
Wang Y; Siricilla S; Aleiwi BA; Kurosu M
Chemistry; 2013 Oct; 19(41):13847-58. PubMed ID: 24014478
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
Hotoda H; Daigo M; Furukawa M; Murayama K; Hasegawa CA; Kaneko M; Muramatsu Y; Ishii MM; Miyakoshi S; Takatsu T; Inukai M; Kakuta M; Abe T; Fukuoka T; Utsui Y; Ohya S
Bioorg Med Chem Lett; 2003 Sep; 13(17):2833-6. PubMed ID: 14611839
[TBL] [Abstract][Full Text] [Related]
8. Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.
Biecker AL; Liu X; Thorson JS; Yang Z; Van Lanen SG
Molecules; 2019 Jan; 24(3):. PubMed ID: 30691073
[No Abstract] [Full Text] [Related]
9. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
10. Concise synthesis of capuramycin.
Kurosu M; Li K; Crick DC
Org Lett; 2009 Jun; 11(11):2393-6. PubMed ID: 19405507
[TBL] [Abstract][Full Text] [Related]
11. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
12. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
13. Studies on novel bacterial translocase I inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G.
Muramatsu Y; Ishii MM; Inukai M
J Antibiot (Tokyo); 2003 Mar; 56(3):253-8. PubMed ID: 12760681
[TBL] [Abstract][Full Text] [Related]
14. Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics.
Kimura KI
J Antibiot (Tokyo); 2019 Dec; 72(12):877-889. PubMed ID: 31582803
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD
Wang X; Ahn YM; Lentscher AG; Lister JS; Brothers RC; Kneen MM; Gerratana B; Boshoff HI; Dowd CS
Bioorg Med Chem Lett; 2017 Sep; 27(18):4426-4430. PubMed ID: 28827112
[TBL] [Abstract][Full Text] [Related]
16. Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.
San Jose G; Jackson ER; Haymond A; Johny C; Edwards RL; Wang X; Brothers RC; Edelstein EK; Odom AR; Boshoff HI; Couch RD; Dowd CS
ACS Infect Dis; 2016 Dec; 2(12):923-935. PubMed ID: 27676224
[TBL] [Abstract][Full Text] [Related]
17. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M
J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054
[TBL] [Abstract][Full Text] [Related]
18. DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
Mitachi K; Kansal RG; Hevener KE; Gillman CD; Hussain SM; Yun HG; Miranda-Carboni GA; Glazer ES; Clemons WM; Kurosu M
J Med Chem; 2020 Oct; 63(19):10855-10878. PubMed ID: 32886511
[TBL] [Abstract][Full Text] [Related]
19. Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitors.
Sahu NU; Singh V; Ferraris DM; Rizzi M; Kharkar PS
Bioorg Med Chem Lett; 2018 Jun; 28(10):1714-1718. PubMed ID: 29699922
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis.
Green KD; Chen W; Garneau-Tsodikova S
ChemMedChem; 2012 Jan; 7(1):73-7. PubMed ID: 21898832
[No Abstract] [Full Text] [Related]
[Next] [New Search]
